Navigation Links
MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine
Date:1/26/2009

MOUNTAIN VIEW, Calif., Jan. 26 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has completed patient enrollment in the efficacy portion of its initial Phase 3 clinical trial evaluating MAP0004, the company's novel, orally inhaled product candidate for the acute treatment of migraine.

"In our Phase 2 clinical trial, MAP0004 demonstrated the potential to be both fast acting and long-lasting, providing pain relief in as fast as ten minutes with relief lasting for 24 and 48 hours, so we believe that MAP0004 has the potential to be a first-line therapy for migraine patients. We would like to thank our investigators as well as their patients for their strong interest and support for studying the potential benefits of MAP0004," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "We look forward to announcing clinical data from the efficacy portion of the trial in the first half of this year."

The Phase 3 multi-center, randomized, double-blind, placebo-controlled trial in approximately 850 migraine sufferers is evaluating the safety and efficacy of MAP0004 as a potential acute treatment for migraine. The primary efficacy endpoints are pain relief and freedom from nausea, photophobia and phonophobia as measured at two hours after dosing. The study is also evaluating earliest onset of pain relief, pain relief at 10 minutes, and sustained pain relief and freedom at 24 and 48 hours. Patients enrolled in the trial are being evaluated for the treatment of a single migraine and may continue in a long-term safety arm of the trial, enrollment in which is ongoing. MAP Pharmaceuticals is conducting this first Phase 3 trial pursuant to a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration.

MAP0004 is a novel, o
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Axikin Pharmaceuticals Spins out of Actimis
2. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
3. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
4. Cumberland Pharmaceuticals Appoints Lee Product Director
5. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
6. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
7. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
8. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
9. Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
10. MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs
11. Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 22, 2014 Currently ... Sartorius, A & D Weighing, Rice Lake, and ... Semi-Micro Balance . The Sartorius CPA Semi-Micro Balance ... affordable high-quality, precise, and user-friendly laboratory balance. , ... laboratory equipment, their laboratory balances are well known ...
(Date:10/22/2014)... Physicians Choice Laboratory Services (PCLS) ... which enables healthcare providers to individualize therapeutic treatments ... results, healthcare providers are better able to assess ... minimizing risks for adverse drug reactions and interactions. ... FDA [1] more than 2.2 million adverse drug ...
(Date:10/22/2014)... 2014   Synthetic Biologics, Inc. (NYSE MKT: ... serious infections and diseases, announced today that the U.S. ... Allowance for a composition of matter patent application that ... program, SYN-004. This is Synthetic Biologics, first allowed patent ... adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... YORK , Oct. 22, 2014 Nuvilex, ... Federation, approximately 400 million people worldwide are living with ... million people by 2030.  The global market for diabetes ... 2012 approximately 330,000 people worldwide died from pancreatic cancer.  ... death due to cancer in the United ...
Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
... RATON, Fla., April 30 Siemens Communications, ... achievement awards. The,winners, members of the Siemens ... Siemens Enterprise Partner Forum held in March ... ), The Siemens Enterprise Partner ...
... HALIFAX, April 30 /PRNewswire/ - ImmunoVaccine Technologies Inc. ... platform, a,novel depot vaccine delivery system used to ... filed additional patents to protect the,DepoVax(TM) concept., ... DepoVax(TM),is highly effective with a single dose," remarked ...
... to Head New Division, AUSTIN, Texas, April ... marketing to customers across the entire healthcare,continuum, HC&B ... healthcare firms, has established a full-scale digital,division., ... clients expanded,digital capabilities, including strategy; web design and ...
Cached Biology Technology:Black Box Network Services, ABTECH, Verizon Business and Wyle Named Top Siemens Reseller Partners 2Black Box Network Services, ABTECH, Verizon Business and Wyle Named Top Siemens Reseller Partners 3Black Box Network Services, ABTECH, Verizon Business and Wyle Named Top Siemens Reseller Partners 4ImmunoVaccine Technologies Patents DepoVax(TM) Vaccine Platform 2HC&B Healthcare Launches HC&B Digital 2HC&B Healthcare Launches HC&B Digital 3
(Date:10/25/2014)...   MedNet Solutions , a global life sciences ... pleased to announce the 2014 iMedNet User ... held in Bloomington, Minnesota on ... attendance and promises to be informative, productive and enjoyable ... the meeting is iMedNet™ EDC , ...
(Date:10/25/2014)... , Oct. 22, 2014 This report ... a relatively new space in heavy pursuit of research ... unique to miRNAs compared to other RNA components. miRNA,s ... it a novel candidate for use as a biomarker ... of miRNA-based microarrays and diagnostics for the advancement in ...
(Date:10/25/2014)... -- A recent report, "Genetic Testing Market Outlook 2018", ... genetic testing market. A comprehensive introduction of gene-based tests, ... report. On account of our analysis of the past ... challenges; forecast for genetic testing has been drawn, according ... a CAGR of around 9% during 2013-2018. Our ...
Breaking Biology News(10 mins):MedNet Solutions To Host Third Annual iMedNet User Group Meeting 2MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors 2Genetic Testing Market Outlook 2018 2
... among the enemy has been occasionally practiced over ... chilling than ever because of rapidly expanding knowledge ... to wreak havoc in complex, interdependent societies. The ... strong microbial forensic program to attribute and prosecute ...
... that a molecule called DJ-1 is likely to be ... regulation of the well-known tumor suppressor, PTEN. The research, ... important implications for determining the prognosis of some human ... for cancer therapy. , The phosphatidylinositol 3' kinase signaling ...
... of the journal Cancer Cell describes a small molecule inhibitor ... avenue for targeted cancer therapy. The compound, ON01910, is a ... and has low toxicity. The results of this study have ... clinical trials. , Plk1 is a molecule that plays a ...
Cached Biology News:Microbial forensics: The next great forensic challenge 2Microbial forensics: The next great forensic challenge 3Microbial forensics: The next great forensic challenge 4Scientists identify molecule that regulates well-known tumor suppressor 2New drug shows promise as powerful anticancer agent 2
... cells permits studies of protein-protein interactions, protein ... transcription factor-mediated gene regulation. The most rapid ... specific protein in a mammalian cell is ... cell. ProteoJuice Protein Transfection Reagent is an ...
... is an innovative reagent for highly efficient ... of living cells. Unlike DNA transfection, with ... amount and timing of exogenous proteins in ... can now be studied. Real time ...
... automated instrument with a thin silicon strain ... light or fluorescence microscopy. Biaxial strain that ... cells can be simulated by mechanical stretching ... axis of our strain chamber. Strain can ...
... SpliceArray Services is a ... industrial and academic researchers. ... Provider of Agilent, and we ... all Agilent catalogue arrays. ...
Biology Products: